Tablet compression: changing trends, more demands - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tablet compression: changing trends, more demands


Pharmaceutical Technology Europe
Volume 22, Issue 6

The full version of this tabletting feature can be read in the June issue of our digital magazine: http://www.pharmtech.com/ptedigital0610


Jan Vogeleer
The market for tablet compression technology and the demands placed on equipment manufacturers have changed quite significantly in recent years. This has been driven by a number of factors. Firstly, the pharmaceutical industry has seen a significant shift of investments in solid dosage production equipment towards generics and contract manufacturing. As the companies in this segment of the market are, by nature, strongly focused on cost reduction, a big emphasis is placed on productivity, flexibility and process yield (i.e., minimal product loss). Equipment cost and reliability, as well as fast on-site assistance have also become key selection criteria. R&D-based companies have also been forced to follow this cost reduction trend.

Secondly, the meteoric growth of new pharmaceutical markets in the Middle East and the Far East (e.g., India, China, South Korea) has led investments in solid dosage equipment in these regions to surpass the investments made in North America and Europe. This puts an increased pressure on equipment price and has resulted in several Western based companies moving the design, manufacture and assembly of their equipment to Asia.

Finally, with the increased potency of new APIs, there is a growing need for better protection of the operator against the effects of pharmaceutical product processing. Operator exposure can be reduced either through the use of Personal Protective Equipment (PPE) or by making the equipment highly contained. The latter approach is the preferred solution, primarily for ergonomic reasons and because it offers a more efficient way of protecting the environment in general, as well as the facility and other personnel.

Technology breakthroughs

Although the operating principle and fundamental design of the rotary tablet press have not changed for decades, multiple machine design improvements have been developed and implemented by various suppliers to reduce cost and lead time, and more importantly, to increase productivity, flexibility and safety performance.

The initial emphasis of innovation was on reducing the amount of time required for machine cleaning and product changeover. The first significant change was the "exchangeable turret", introduced to the market by Fette in the early 1990s and now available from nearly all suppliers. While this machine feature offers great flexibility with regard to the tooling types that can be used on the same machine, the time saved for cleaning and format changeover is limited; after removal of the turret, the complex inside of the tablet press still needs to be cleaned. Therefore, openness of structure and accessibility were further improved (e.g., the XL range by Korsch). Taking a different approach to the challenge, IMA came up with a revolutionary design without exchangeable turret, but with centrifugal die filling and Clean-In-Place capability. Whilst in early 2000, GEA Courtoy introduced the "Exchangeable Compression Module", a concept that made extremely fast product changeover possible thanks to off-line cleaning, and also offered n increased level of dust containment compared with conventional removable turret machines.

In more recent years, various improvements in machine designs have been made to increase the instantaneous output of tablet presses. To achieve this, it was necessary to enhance the efficiency of the forced paddle feeders to guarantee uniform die filling — and consequently tablet weight stability — at these higher outputs. The next step was to increase the number of punch stations on the turret (e.g., die plate segments by Fette; exchangeable die disc with die shells by GEA Courtoy) and/or to increase the rotation speed of the turret. When increasing the rpm of the turret, the compression dwell time for each individual tablet shortens, often resulting in insufficient hardness, capping or lamination. Methods that have now been developed to maintain a longer dwell time include air compensation and, to a lesser extent, larger compression rollers and punches with special head design.

The last 10 years have also seen a significant effort to design complete tablet production lines to handle potent and toxic drugs. As the powder infeed, tablet handling, sampling and tablet collection all have to be performed under "high containment" conditions, it became imperative to design complete lines integrating the peripheral equipment, such as powder discharge station, tablet de-duster, metal detector, dust extractor and tablet analyser. Initially, the most common technique was to build isolators around the equipment and provide wash-in-place capability. However, the latest design trend is toward containment at the source and off-line washing, as these concepts allow equipment to be smaller, easier to install and operate, and lower priced.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here